Nyrada (ASX:NYR) ended the June quarter with a cash balance of about AU$8.4 million, up from AU$6.7 million as of March 31, according to a Monday filing with the Australian bourse.

Cash operating outflows for the June quarter totaled about AU$1.7 million, offset by AU$60,000 of interest income and the receipt of a roughly AU$2.5 million research and development tax incentive from the Australian government, per the filing.

The company said its phase 2a clinical trial of Xolatryp in heart attack patients remains on track for completion next year, with the final patient expected to be dosed in mid-2027.

Nyrada shares fell 1% in recent Monday trade.